Description
Progenity, Inc. is a biotechnology company. The Company is engaged in developing and commercializing molecular testing products in the fields of women's health, gastrointestinal health and oral biotherapeutics.
It applies multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. The Company’s molecular tests are: Innatal Prenatal Screen, Preparent Carrier Test, Riscover Hereditary Cancer Test, and Resura Prenatal Test for Monogenic Disease.
The Company is also developing its pipeline products, such as Preecludia pre-eclampsia rule-out test, Drug Delivery System (DDS) platform, and Oral Biopharmaceutical Delivery System (OBDS). It is also developing an ingestible capsule platform designed to help diagnose and treat gastrointestinal (GI) disorders.
